Medicenna Therapeutics Ownership
| MDNA Stock | CAD 1.72 0.10 6.17% |
Shares in Circulation | First Issued 2015-06-30 | Previous Quarter 73.6 M | Current Value 76.8 M | Avarage Shares Outstanding 39.6 M | Quarterly Volatility 24.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Medicenna |
Medicenna Stock Ownership Analysis
About 22.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.38. Medicenna Therapeutics last dividend was issued on the 3rd of March 2017. The entity had 1:14 split on the 3rd of March 2017. Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. MEDICENNA THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 7 people. To find out more about Medicenna Therapeutics Corp contact the company at 416 648 5555 or learn more at https://www.medicenna.com.Medicenna Therapeutics Outstanding Bonds
Medicenna Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medicenna Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medicenna bonds can be classified according to their maturity, which is the date when Medicenna Therapeutics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Medicenna Stock
| 0.56 | AMZN | Amazon CDR | PairCorr |
| 0.55 | BOFA | Bank of America | PairCorr |
| 0.48 | JPM | JPMorgan Chase | PairCorr |
| 0.41 | BRK | Berkshire Hathaway CDR | PairCorr |
| 0.32 | TD-PFD | Toronto Dominion Bank Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.